MedTrace Logo

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

NCT03726775 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2025-05-07

No results posted yet for this study

Summary

This study evaluate the regional (neck) nodal control of durvalumab in combination with RT restricted to the primary tumor and the immediately adjacent nodal level (i.e. without prophylactic neck irradiation) in N0 patients with SCCHN.

Conditions

  • HNSCC

Interventions

DRUG

Durvalumab

Infusion of durvalumab during RT and after RT during 6 months

Sponsors & Collaborators

  • UNICANCER

    collaborator OTHER

  • Center Eugene Marquis

    collaborator OTHER

  • Groupe Oncologie Radiotherapie Tete et Cou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2026-07-31
Completion
2026-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726775 on ClinicalTrials.gov